Biopharma Firms That Secure Corporate Venture Investment 'More Likely to Be Acquired'

Corporate venture funding is a good predictor for licensing deals, acquisition and IPOs, an analysis has revealed.

Biopharmaceutical companies that attract corporate venture funding are more likely to enter into licensing deals, be acquired or go public, a study has found.

Financial services firm Burrill & Company looked at all therapeutics venture investments made between January 1st 2000 and December 31st 2011 in the S&P Capital IQ database.

During that time, 2,907 companies received disclosed venture capital funding and 286 of these (9.9 per cent) obtained funding - at least in part - from a corporate venture fund.

Researchers found that of those companies that received corporate venture funding, 24.5 per cent were eventually acquired, compared with just 14.4 per cent of those that did not attrac